Cargando…

Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases

Anti-SS-A antibodies are often sought for in autoimmune diseases diagnosis. Two different target proteins have actually been identified: Ro52 and Ro60. Clinical and immunological associations seem different depending on anti-Ro52 or anti-Ro60 antibodies presence. However, due to a heterogeneous pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Robbins, Ailsa, Hentzien, Maxime, Toquet, Segolene, Didier, Kevin, Servettaz, Amelie, Pham, Bach-Nga, Giusti, Delphine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423153/
https://www.ncbi.nlm.nih.gov/pubmed/30915082
http://dx.doi.org/10.3389/fimmu.2019.00444
_version_ 1783404492207685632
author Robbins, Ailsa
Hentzien, Maxime
Toquet, Segolene
Didier, Kevin
Servettaz, Amelie
Pham, Bach-Nga
Giusti, Delphine
author_facet Robbins, Ailsa
Hentzien, Maxime
Toquet, Segolene
Didier, Kevin
Servettaz, Amelie
Pham, Bach-Nga
Giusti, Delphine
author_sort Robbins, Ailsa
collection PubMed
description Anti-SS-A antibodies are often sought for in autoimmune diseases diagnosis. Two different target proteins have actually been identified: Ro52 and Ro60. Clinical and immunological associations seem different depending on anti-Ro52 or anti-Ro60 antibodies presence. However, due to a heterogeneous presentation in the literature, some immunology laboratories in France have stopped providing anti-Ro52 antibody findings. We report here a new hospital study designed to determine the diagnostic utility of the separate detection of anti-Ro52 and anti-Ro60 antibodies. We conducted a retrospective, observational study, including every adult patient with positive antinuclear antibodies (ANA) tested in our immunology laboratory, and associated with anti-Ro52 and/or anti-Ro60 antibodies, between 2011 and 2014. Out of 13032 sera tested for ANA, 399 adults had antibodies to Ro52 and/or Ro60; 81.7% were female, with a mean age of 54.5 ± 17.0 years. Anti-Ro52 antibodies were found in 75.7% of the patients and anti-Ro60 antibodies in 56.9%. Among them, 43.1% were classified in the Ro52 + Ro60- group, 32.6% in the Ro52 + Ro60 + group and 24.3% in the Ro52-Ro60+ group. In the Ro52-Ro60+ group, systemic lupus was the most frequent diagnosis (48.5%), with a possible association with antiphospholipid antibodies (anti-cardiolipin antibodies: OR 2.5 (CI95 [1.0–5.0], p = 0.05) and lupus anticoagulant {OR 3.6 (CI95 [1.10–10.0] p = 0.02)}. In the Ro52+Ro60+, primary Sjögren Syndrome was the most likely (OR 4.2 95% CI [2.1–8.3] p < 10(−4)), especially in patients Ro52+Ro60+La+. Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4–81.7], p = 0.02) and inflammatory rheumatism (OR 4.6 [1.6–13.8], p = 0.006) in contrast to systemic lupus (OR 0.2 [0.1–0.3], p < 10(−4)) or primary Sjögren's syndrome (OR 0.1 [0.06–0.2], p < 10(−4)). We therefore suggest that, when anti-ENA antibodies are prescribed, it should include separate anti-Ro52 and anti-Ro60 antibodies determination. To go even further, we would like to suggest a change in ENA nomenclature to avoid confusion, abandoning the anti-SS-A label in favor of the anti-Ro52/TRIM21 or anti-Ro60 antibody for a clearer designation.
format Online
Article
Text
id pubmed-6423153
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64231532019-03-26 Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases Robbins, Ailsa Hentzien, Maxime Toquet, Segolene Didier, Kevin Servettaz, Amelie Pham, Bach-Nga Giusti, Delphine Front Immunol Immunology Anti-SS-A antibodies are often sought for in autoimmune diseases diagnosis. Two different target proteins have actually been identified: Ro52 and Ro60. Clinical and immunological associations seem different depending on anti-Ro52 or anti-Ro60 antibodies presence. However, due to a heterogeneous presentation in the literature, some immunology laboratories in France have stopped providing anti-Ro52 antibody findings. We report here a new hospital study designed to determine the diagnostic utility of the separate detection of anti-Ro52 and anti-Ro60 antibodies. We conducted a retrospective, observational study, including every adult patient with positive antinuclear antibodies (ANA) tested in our immunology laboratory, and associated with anti-Ro52 and/or anti-Ro60 antibodies, between 2011 and 2014. Out of 13032 sera tested for ANA, 399 adults had antibodies to Ro52 and/or Ro60; 81.7% were female, with a mean age of 54.5 ± 17.0 years. Anti-Ro52 antibodies were found in 75.7% of the patients and anti-Ro60 antibodies in 56.9%. Among them, 43.1% were classified in the Ro52 + Ro60- group, 32.6% in the Ro52 + Ro60 + group and 24.3% in the Ro52-Ro60+ group. In the Ro52-Ro60+ group, systemic lupus was the most frequent diagnosis (48.5%), with a possible association with antiphospholipid antibodies (anti-cardiolipin antibodies: OR 2.5 (CI95 [1.0–5.0], p = 0.05) and lupus anticoagulant {OR 3.6 (CI95 [1.10–10.0] p = 0.02)}. In the Ro52+Ro60+, primary Sjögren Syndrome was the most likely (OR 4.2 95% CI [2.1–8.3] p < 10(−4)), especially in patients Ro52+Ro60+La+. Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4–81.7], p = 0.02) and inflammatory rheumatism (OR 4.6 [1.6–13.8], p = 0.006) in contrast to systemic lupus (OR 0.2 [0.1–0.3], p < 10(−4)) or primary Sjögren's syndrome (OR 0.1 [0.06–0.2], p < 10(−4)). We therefore suggest that, when anti-ENA antibodies are prescribed, it should include separate anti-Ro52 and anti-Ro60 antibodies determination. To go even further, we would like to suggest a change in ENA nomenclature to avoid confusion, abandoning the anti-SS-A label in favor of the anti-Ro52/TRIM21 or anti-Ro60 antibody for a clearer designation. Frontiers Media S.A. 2019-03-12 /pmc/articles/PMC6423153/ /pubmed/30915082 http://dx.doi.org/10.3389/fimmu.2019.00444 Text en Copyright © 2019 Robbins, Hentzien, Toquet, Didier, Servettaz, Pham and Giusti. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Robbins, Ailsa
Hentzien, Maxime
Toquet, Segolene
Didier, Kevin
Servettaz, Amelie
Pham, Bach-Nga
Giusti, Delphine
Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases
title Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases
title_full Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases
title_fullStr Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases
title_full_unstemmed Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases
title_short Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases
title_sort diagnostic utility of separate anti-ro60 and anti-ro52/trim21 antibody detection in autoimmune diseases
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423153/
https://www.ncbi.nlm.nih.gov/pubmed/30915082
http://dx.doi.org/10.3389/fimmu.2019.00444
work_keys_str_mv AT robbinsailsa diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases
AT hentzienmaxime diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases
AT toquetsegolene diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases
AT didierkevin diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases
AT servettazamelie diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases
AT phambachnga diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases
AT giustidelphine diagnosticutilityofseparateantiro60andantiro52trim21antibodydetectioninautoimmunediseases